Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,130.00
(
0.48%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.04
(
-0.61%
)
Bitcoin
73,867.23
(
-0.10%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 115713

Wednesday, 05/11/2011 1:12:02 AM

Wednesday, May 11, 2011 1:12:02 AM

Post# of 257253
Roche submits PLX4032 NDA/MAA for BRAF-V600+ melanoma:

http://finance.yahoo.com/news/New-Drug-Applications-bw-1675487810.html?x=0&.v=1

PLX4032 (a/k/a vemurafenib) is the drug Roche licensed from Plexxikon that was the subject of a recent series in the NY Times (#msg-46899517, #msg-54567652). The phase-3 data (#msg-58950046) were sufficiently compelling that Daiichi Sanko bought Plexxikon for almost $1B two months ago (#msg-60475592).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now